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. Importantly, despite its nomenclature as a constant domain, the antibody Fc domain does not have constant function, and is strongly modulated by IgG subclass (IgG1-4) and glycosylation at Asparagine 297 [4] [5] [6] . Thus, this method to study functional differences of antigen-specific antibodies in clinical samples will facilitate correlation of the phagocytic potential of antibodies to disease state, susceptibility to infection, progression, or clinical outcome.
Furthermore, this effector function is particularly important in light of the documented ability of antibodies to enhance infection by providing pathogens access into host cells via Fc receptor-driven phagocytosis 7 . Additionally, there is some evidence that phagocytic uptake of immune complexes can impact the Th1/Th2 polarization of the immune response 8 .
Here, we describe an assay designed to detect differences in antibody-induced phagocytosis, which may be caused by differential IgG subclass, glycan structure at Asn297, as well as the ability to form immune complexes of antigen-specific antibodies in a high-throughput fashion. To this end, 1 μm fluorescent beads are coated with antigen, then incubated with clinical antibody samples, generating fluorescent antigen specific immune complexes. These antibody-opsonized beads are then incubated with a monocytic cell line expressing multiple FcγRs, including both inhibitory and activating. Assay output can include phagocytic activity, cytokine secretion, and patterns of FcγRs usage, and are determined in a standardized manner, making this a highly useful system for parsing differences in this antibody-dependent effector function in both infection and vaccine-mediated protection 9 .
Video Link
The video component of this article can be found at http://www.jove.com/video/3588/ Protocol 1. Culture Phagocytic Cells 
Prepare Biotinylated Antigen
1. Calculate the amount of sulfo-NHS LC biotin reagent kit necessary to biotinylate the target antigen of interest according to the manufacturer's instructions. 2. Dissolve the biotinylation reagent in water and immediately add the calculated amount to antigen in a buffer that does not contain primary amines. Allow the reaction to proceed for 1 hour at room temperature, mixing occasionally. 3. Remove excess, unconjugated biotin by buffer exchange in an Amicon centrifugal concentration unit of an appropriate molecular weight cutoff to retain the target antigen. Add sample to the top chamber of the concentration unit and add PBS to bring the total volume up to 15 mL fill line. Centrifuge at 4000 x g to bring volume down to approximately 1.5 mls. Repeating this process twice will remove 99% of the free biotin to ensure maximal coating of antigen to beads. NOTE: Signal to noise may be improved by determining the optimal bead:antibody:THP-1 cell ratios for a given antigen and antibody source.
Flow Cytometric Analysis
1. Remove 100 μl of supernatant from each well being careful not to disturb the cell pellet. Supernatant can be saved if cytokine secretion determinations or other analyses are desired. 2. For fixation, add 100 μl of 4% paraformaldehyde to each well and pipet to resuspend and mix cells. 
Representative Results
There should be clear differentiation of antibody samples from affected and unaffected subjects. Figure 1A presents the FACS histograms of an antibody sample from an HIV negative (black trace) and an HIV positive (gray trace) subject, and demonstrates the increased phagocytosis driven by the presence of antigen-specific antibodies.
Optimal sensitivity of the assay is dependent on saturation of the beads with biotinylated antigen. Figure 1B presents the phagocytosis observed when beads coated with differing amounts of antigen were opsonized with 3 control monoclonal antibodies (including a non-binding antibody, triangles), and establishes 2μg antigen/μl beads as a saturating concentration for this antigen.
A dose-response curve is presented in Figure 2 , and demonstrates the differential capacity of subject antibody samples to induce phagocytosis over an antibody concentration range of 0.05-5 μg/ml. This differential phagocytosis may be driven by either differences in titer or Fc domain properties such as IgG subclass and glycosylation state. 
Discussion
The assay described here allows high-throughput analysis of the phagocytic activity of clinical antibody samples by utilizing a monocytic cell line long utilized to study phagocytic processes 10 and plate based automated flow cytometry. This assay is advantageous over others in its ability to precisely characterize antigen-specific antibody subsets, allowing not only for study of differences in phagocytosis driven by diseasespecific antibodies from different subjects, but also study of multiple antigen specificities within the same subject. Because antibody recruitment of innate effector cells, including monocytes and other antigen presenting cells strongly impacts disease outcome [11] [12] [13] , and is biologically variable depending antibody geometry, IgG subclass, and glycosylation at Asparagine297 of the Fc domain [14] [15] [16] , this method provides for evaluation of a critical antibody mechanism of action. Furthermore, because antibody-mediated phagocytosis is exploited by some pathogens during the course of infection 7, 17, 18 , this assay holds promise in evaluation of the process of antibody-dependent enhancement, and highlights the dual nature of phagocytosis as a potentially protective, as well as potentially detrimental antibody activity.
The assay described can be utilized to analyze antibodies from clinical samples of patient populations, but also of vaccinees, and may be adapted to utilize serum rather than purified IgG. Additionally, cytokine secretion in response to phagocytosis can be analysed from the culture supernatant, and the influence of specific FcR can be determined by using FcR-blocking antibodies, allowing not only differences in phagocytic potency to be determined, but downstream signaling events, with insight into mechanism, and may help to resolve and refine understanding of this immune mechanism.
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